Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 24,052 Shares of Stock

Key Points

• Insider sale: Director Erin Pennock Foff sold 24,052 shares on May 6 at an average of $28.76 (~$691,736); across May 4–6 she sold a total of 50,280 shares for roughly $1.43M, with the May 6 trade executed under a pre‑arranged Rule 10b5‑1 plan and leaving her with 350,497 shares (~$10.08M), a 6.42% ownership reduction.
• Market reaction & context: MPLT rose about 4.0% to $29.04 on Wednesday (volume 267,979 vs. avg 342,018), has a $1.24B market cap, a 50‑day SMA of $22.60 and a one‑year range of $12.24–$33.28.
• Fundamentals vs. sentiment: The company reported a sizable Q1 EPS miss (‑$2.47 vs. consensus ‑$1.05), yet analysts remain generally positive (consensus "Moderate Buy" with an average target ~$34.43 and several recent Buy initiations, including HC Wainwright at $45).

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider Erin Pennock Foff sold 24,052 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $691,735.52. Following the completion of the sale, the insider owned 350,497 shares of the company's stock, valued at approximately $10,080,293.72. This trade represents a 6.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total value of $298,243.20.
• On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total value of $437,629.92.

Maplight Therapeutics Stock Up 4.0%

Shares of MPLT stock traded up $1.12 during trading on Wednesday, hitting $29.04. The company had a trading volume of 267,979 shares, compared to its average volume of 342,018. The company has a market cap of $1.24 billion and a price-to-earnings ratio of -0.73. The stock's 50-day simple moving average is $22.60. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.05) by ($1.42). On average, analysts predict that Maplight Therapeutics, Inc. will post -3.96 EPS for the current year.

Hedge Funds Weigh In On Maplight Therapeutics

Large investors have recently modified their holdings of the business. Strs Ohio bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the fourth quarter worth $70,000. New York State Common Retirement Fund bought a new position in Maplight Therapeutics during the fourth quarter worth $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter worth $172,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics during the fourth quarter worth $205,000.

Analyst Ratings Changes

Several analysts recently issued reports on MPLT shares. TD Cowen started coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a "buy" rating on the stock. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a "sell (e)" rating on the stock. HC Wainwright started coverage on shares of Maplight Therapeutics in a research report on Monday. They set a "buy" rating and a $45.00 price target on the stock. Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a "buy" rating and a $37.00 price target on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They issued a "buy" rating and a $35.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $34.43.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.